证券代码：688366 证券简称：昊海生科 公告编号：2025-025 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/8/17 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 2024 8 16 8 | 日~2025 | 年 | 月 | 日 15 | | 预计回购金额 | 10,000.00万元~20,000.00万元 | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | □为维护公司价值及股东权益 | | | | | | 累计已回购股数 | 1,832,421股 | | | | | | 累计已回购股数占总股本比例 | 0.79% | | | | | | 累计已回购金额 | 10,390.54万元 | | | | | | 实际回购价格区间 | 49.25元/股~63.58元/股 | | | | | 一、 回购 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年5月27日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | | A 股（上海證券交易所科創板，股份代號：688366） | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年5月27日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | | A 股（上海證券交易所科創板，股份代號：688366） | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存 ...

Core Viewpoint - Haohai Biological Technology Co., Ltd. is experiencing a stock price increase and has a lower PE ratio compared to the industry average, indicating potential investment opportunities in the medical device sector [1][2]. Company Summary - Haohai Biological Technology's stock closed at 52.86 yuan, up 3.18%, with a rolling PE ratio of 29.83 times and a total market capitalization of 12.327 billion yuan [1]. - The company operates in the medical device and pharmaceutical sectors, focusing on the research, production, and sales of products such as ophthalmic viscoelastic devices, artificial lenses, and hyaluronic acid [1]. - The latest quarterly report for Q1 2025 shows a revenue of 619 million yuan, a year-on-year decrease of 4.25%, and a net profit of 90.3121 million yuan, down 7.41%, with a gross profit margin of 69.52% [1]. Industry Summary - The average PE ratio for the medical device industry is 49.51 times, with a median of 36.17 times, positioning Haohai Biological at the 66th rank within the industry [2]. - The industry has a total market capitalization of 106.36 billion yuan, indicating a significant market size and potential for growth [2].

Core Viewpoint - The medical beauty industry is experiencing a significant performance divergence among listed companies, driven by a shift from hyaluronic acid to collagen products, indicating a potential restructuring of industry value logic [1][3]. Group 1: Performance Analysis - In 2024, the performance of upstream medical beauty companies showed significant divergence, with companies like Juzi Biological and Jinbo Biological leading with high growth rates, while major hyaluronic acid players like Aimeike, Huaxi Biological, and Haohai Biological faced pressure [2][3]. - Aimeike's revenue growth slowed to 5.45%, the lowest since its listing, while Huaxi Biological's revenue declined by 11.61% and net profit dropped by 70.59% [3][5]. - Juzi Biological achieved revenue of 5.539 billion, a year-on-year increase of 57.2%, and a net profit of 2.062 billion, up 42.4% [5][7]. Group 2: Market Trends - The market for recombinant collagen products in China is projected to grow from 18.5 billion in 2022 to 108.3 billion by 2027, with a compound annual growth rate of 42.4% [7]. - Companies are increasingly entering the collagen market, including Aimeike and Huaxi Biological, which are exploring new opportunities in this segment [7][8]. - Huaxi Biological is developing proprietary recombinant human collagen products that have entered clinical trials, indicating a strategic shift towards innovative product development [7].

Group 1 - The core issue revolves around the investigation of the controlling shareholder, Jiang Wei, for insider trading, which has raised concerns about potential related party transactions and market trust in the company [1][2] - The company reported a significant decline in revenue growth, with a 1.64% increase projected for 2024, marking a four-year low, while traditional business segments are experiencing revenue declines [2][3] - The company's reliance on acquisitions for growth is being questioned, as the integration of acquired entities has shown mixed results, and R&D investment has decreased significantly [3][4] Group 2 - The company faces internal challenges, including governance issues and declining performance, while external pressures from industry competition and pricing strategies are intensifying [4] - The medical aesthetics sector is becoming increasingly competitive, with other players also facing challenges, indicating a potential end to the high-growth phase for hyaluronic acid products [3][4] - To regain market confidence, the company must address compliance, innovate in R&D, and diversify its business operations [4]

上海昊海生物科技股份有限公司的主营业务是医疗器械和药品研发、生产和销售。公司的主要产品是眼 科粘弹剂、人工晶状体、视光材料、视光终端产品、玻尿酸、人表皮生长因子、射频及激光设备、玻璃 酸钠注射液、医用几丁糖（关节腔注射用）、医用几丁糖（防粘连用）、医用透明质酸钠凝胶、胶原蛋 白海绵。 5月12日，昊海生科今日收盘51.15元，下跌1.63%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到28.87倍，总市值119.28亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均49.84倍，行业中值36.59倍，昊海生科排 名第65位。 截至2025年一季报，共有3家机构持仓昊海生科，其中基金3家，合计持股数246.35万股，持股市值1.46 亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入6.19亿元，同比-4.25%；净利润9031.21万元，同 比-7.41%，销售毛利率69.52%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)65昊海生科28.8728.372.10119.28亿行业平均 49.8445.684.61105.51亿行业中值36.5938.052. ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | H 股 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | H 股 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 ...

Core Viewpoint - The company is facing significant challenges, including insider trading investigations, declining revenues and profits, and increased operational costs, leading to a loss of investor confidence and a substantial decrease in market capitalization [1][2][4]. Financial Performance - In Q1 2025, the company reported a revenue of 619 million yuan, a year-on-year decrease of 4.25%, and a net profit of 90.31 million yuan, down 7.41% [3][4]. - For the full year 2024, the company achieved a revenue of 2.698 billion yuan, a slight increase of 1.64%, but net profit fell by 8.74% [4][10]. - The medical beauty segment generated 1.195 billion yuan in revenue, accounting for 44.38% of total revenue, with a growth rate of 13.08% [5][6]. Segment Analysis - The hyaluronic acid products contributed 742 million yuan, showing a growth of 23.23%, but the growth rate has significantly slowed compared to previous years [6][7]. - The ophthalmology segment's revenue was 858 million yuan, down 7.60%, primarily due to price reductions from national procurement policies [8][9]. - The orthopedic segment also faced challenges, with revenue declining by 4.11% to 457 million yuan, impacted by provincial procurement price cuts [9]. Cost Structure - The total cost of the pharmaceutical manufacturing sector increased by 3.77%, with direct materials and labor costs rising by 10.14% and 19.49%, respectively [13][14]. - The medical beauty segment saw manufacturing costs surge by 22.94%, while the ophthalmology segment experienced a decrease in manufacturing costs but an increase in direct labor costs by 22.02% [14][15]. Subsidiary Performance - Several subsidiaries, including Likangrui and Aaren, reported significant losses, totaling over 97 million yuan, which adversely affected the consolidated profit [11][12].